Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.
Prelude Therapeutics Inc. insider ownership update: Krishna Vaddi reported beneficial ownership of 6,745,647 shares of Prelude Therapeutics common stock, representing 13.15% of the class as of December 31, 2025. This includes directly held shares, stock options exercisable within 60 days, and shares held through Sidus Ventures, LLC and several trusts for which he is deemed to have beneficial ownership.
Prelude Therapeutics reported a stock option grant to Chief Chemistry Officer Andrew Combs. On February 4, 2026, he received an employee stock option230,000 shares of common stock at an exercise price of $2.30 per share.
The option vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments (1/48 of the total shares) until fully vested, as long as Combs continues providing service to the company on each vesting date.
Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant on February 4, 2026. The derivative award covers 230,000 shares of common stock at an exercise price of $2.30 per share, with no cash paid for the option itself.
The option vests over time: 25% of the total shares vest on February 4, 2027, and the remaining shares vest in equal monthly installments of 1/48 of the total until fully vested. Following this grant, Scherle beneficially holds 230,000 stock options, all reported as directly owned.
Prelude Therapeutics granted its CLO, CFO and Corporate Secretary Bryant D. Lim an employee stock option covering 275,000 shares of common stock on February 4, 2026. The option has an exercise price of $2.30 per share and is held as a direct ownership position.
The award vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments of 1/48 of the total grant until fully vested, conditioned on Mr. Lim continuing to provide services to the company on each vesting date.
Prelude Therapeutics CEO Krishna Vaddi received a large stock option grant. The Form 4 reports an employee stock option to purchase 837,000 shares of Prelude Therapeutics common stock at an exercise price of $2.30 per share, granted on February 4, 2026.
The option expires on February 3, 2036. It vests 25% on February 4, 2027, then 1/48 of the total shares vests monthly until fully vested, as long as Vaddi continues providing services to the company on each vesting date.
Prelude Therapeutics reported that the U.S. Food and Drug Administration has cleared it to begin a Phase 1 study of PRT12396. This drug is described as a mutant-selective JAK2V617F inhibitor being developed to treat patients with certain myeloproliferative neoplasms, a group of blood cancers. The update was shared via a press release furnished as an exhibit to the report.
Prelude Therapeutics Incorporated furnished an update for investors by making new presentation materials available. The company plans to use this investor presentation in meetings beginning on January 9, 2026, and has attached the materials as Exhibit 99.1. The information in the presentation and the related report is being furnished rather than filed, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities offering documents.
Prelude Therapeutics (PRLD) filed its Q3 2025 10‑Q, reporting revenue of $6.5 million from an amended AbCellera collaboration, total operating expenses of $26.9 million, and a net loss of $19.7 million ($0.26 per share). Cash, cash equivalents, restricted cash and marketable securities were $58.2 million as of September 30, 2025.
Subsequent to quarter‑end, the company received $6 million from an expanded AbCellera agreement and $60 million in capital from Incyte (an initial $35 million in cash plus a $25 million equity investment at $4.00 per share for 6,250,000 non‑voting shares). As of November 10, 2025, 62,865,270 voting and non‑voting common shares were outstanding. Based on preliminary estimates, these funds and existing balances could extend cash runway into 2027; however, the company states that substantial doubt exists about its ability to continue as a going concern.
Management announced a pause of the SMARCA2 degrader program, an ~11% workforce reduction with $0.5 million in one‑time costs, and noted regained compliance with Nasdaq’s $1.00 minimum bid price requirement. Year‑to‑date operating cash use was $79.4 million, partially offset by $113.8 million provided by investing activities from marketable securities maturities.
Prelude Therapeutics (PRLD) furnished an 8-K announcing it issued a press release with financial results for the three months ended September 30, 2025. The press release is provided as Exhibit 99.1, and an investor presentation intended for use by management is included as Exhibit 99.2. The materials are being furnished under Items 2.02 and 7.01 and are not deemed filed or incorporated by reference under the Exchange Act. The filing was signed by Chief Legal Officer, Corporate Secretary, and Chief Financial Officer Bryant Lim.